Compare Dicks Sporting Goods Inc (DKS) vs Summit Therapeutics Inc (SMMT) Price & Performance

DICK'S Sporting Goods (DKS) trades at $134.91, up 2.84% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains solid fundamentals with a P/E of 14.86 and ROE of 18.47%, though recent earnings showed a Q2 2026 miss. Analyst consensus remains strongly positive with 56.9% buy ratings and a $153.30 price target, representing 13.6% upside potential from current levels.

While facing securities litigation headwinds, DKS demonstrates operational strength with $1.31B operating cash flow and consistent dividend payments. The stock offers value with attractive valuation metrics, but investors should monitor the ongoing class action lawsuits and potential impact on near-term sentiment despite the fundamentally sound business model.

Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.

The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.